INSMED Inc INSM
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
-7.47
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $606.4M | -$1.3B | — | -$967.6M | $739.0M |
| 2024 | $363.7M | -$913.8M | — | -$705.8M | $285.4M |
| 2023 | $305.2M | -$749.6M | — | -$549.5M | -$331.9M |
| 2022 | $245.4M | -$481.5M | — | -$410.3M | $88.0M |
| 2021 | $188.5M | -$434.7M | — | -$370.6M | $410.5M |
| 2020 | $164.4M | -$294.1M | — | -$225.6M | $275.9M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Lewis William | Chair and CEO | 2026-06-25 | Option exercise | 12,518 | $30.46 |
| Lewis William | Chair and CEO | 2026-06-25 | Sell | 12,091 | $102.34 |
| Lewis William | Chair and CEO | 2026-06-25 | Option exercise | 8,880 | $17.16 |
| Lewis William | Chair and CEO | 2026-06-25 | Sell | 3,723 | $104.28 |
| Lewis William | Chair and CEO | 2026-06-25 | Sell | 2,456 | $105.27 |
| Lewis William | Chair and CEO | 2026-06-25 | Sell | 1,292 | $106.27 |
| Lewis William | Chair and CEO | 2026-06-25 | Sell | 1,836 | $103.10 |
| Butera Samuele | SVP, GM, Global Respiratory | 2026-06-23 | Grant | 7,342 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.47 (distress)
- Working capital / assets 0.585
- Retained earnings / assets -2.489
- EBIT / assets -0.551
- Equity / liabilities 0.484
Source: SEC EDGAR filings · CIK 0001104506 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.